

Drug Discovery 2016

ACC, LIVERPOOL

13th - 14th October 2016



#ELRIGDD16

Assay Development, Screening & Emerging Technologies

FRIDAY 14TH OCTOBER: ROOM 3

In drug discovery there is an ever-increasing emphasis on the ability to identify high quality hits. This has resulted in the search for new assays and screening paradigms. Technologies already established later in the discovery cascade, such as CETSA and Mass Spec are being applied in earlier in the value chain to deliver new chemical starting points, and the resurgence of interest in phenotypic screening is starting to deliver in terms of hits and novel targets. This session will explore innovative approaches with established and novel platforms using case studies to demonstrate successful applications.

CHAIRS: Michael Dabrowski, Pelago Bioscience and Katy Kettleborough, MRCT

TIME	SPEAKER	TITLE
9:00 - 9:15	Session Chairs	Introduction and Welcome
9:15 - 10:00	Pär Nordland Karolinska Institutet	Proteome Wide CETSA as a New Biophysics Strategy To Map Target Engagement and the Global Cellular Responses to Drugs
10:00 - 10:30	Thomas Lundbäck Karolinska Institutet	Microplate-Based Measurements of Target Engagement in Live Cells With the Cellular Thermal Shift Assay – a Reflection on Screen Results and Quantitative Interpretations
10:30 - 11:00	COFFEE BREAK	
11:00 - 11:30	Keith Breinlinger Berkeley Lights	Rethinking Cell Line Development from Selection to Single Clone
11:30 - 12:00	POSTER TASTERS	
12:00 - 12:30	SNAPSHOT PRESENTATIONS - Genedata AG, BioTek Instruments, Sartorius Stedim Biotech, CORNING LIFE SCIENCES, BMG Labtech, SAL Scientific Limited	
12:30 - 14:00	LUNCH - EXHIBITION - POSTERS	
14:00 - 14:45	PLENARY KEYNOTE: ROOM 3 Professor Carol Robinson Professor of Chemistry, University of Oxford	Mass Spectrometry and its Role in Membrane Protein Drug Discovery
14:45 - 15:15	David Brierley GlaxoSmithKline	Identifying Small Molecule Agonists of Macrophage Phagocytosis Using a High Content Phenotypic Imaging Based Approach
15:15 - 15:45	Mark Stubbs The Institute of Cancer Research (ICR)	Phenotypic Screening to identify inhibitors of the Wnt Pathway
15:45 - 16:15	COFFEE BREAK	
16:15 - 16:45	Jonathan Wingfield AstraZeneca	Assay Development and Delivery of a High Throughput Screen to Identify Inhibitors of Glutathione-Disulfide Reductase: Application of Acoustic Mass Spectrometry
16:45 - 17:15	CLOSE OF CONFERENCE REMARKS - WITH PRIZE DRAW	

www.elrig.org/drug-discovery-2016